(Q35219339)

7 August 2017

1 reference

title

Clinical application of dendritic cells in cancer vaccination therapy (English)

1 reference

7 August 2017

1 reference

1

Inge Marie Svane

1 reference

7 August 2017

4

Hans E Johnsen

1 reference

7 August 2017

Mette Line Soot

2

1 reference

7 August 2017

Søren Buus

series ordinal

3

1 reference

7 August 2017

publication date

1 July 2003

1 reference

Acta Pathologica et Microbiologica Scandinavica

7 August 2017

published in

1 reference

7 August 2017

volume

111

1 reference

7 August 2017

issue

7-8

1 reference

7 August 2017

page(s)

818-834

1 reference

DCs and peripheral T cell tolerance

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Dendritic cell-based therapy: a review focusing on antigenic selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

The control of T cell responses by dendritic cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Interaction of dendritic cells with skin endothelium: A new perspective on immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Phenotypical and functional characterization of clinical grade dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Dendritic cells: On the move from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Dendritic cell vaccination for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Gene-modified dendritic cells for use in tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Viral vectors for dendritic cell-based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Transfected human dendritic cells to induce antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Misconduct trouble brewing in Göttingen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

RNA as a tumor vaccine: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Design and evaluation of antigen-specific vaccination strategies against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Use of overlapping peptide mixtures as antigens for cytokine flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Quantification of antigen specific CD8+ T cells using an ELISPOT assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

A Comparative Study of the Generation of Dendritic Cells from Mobilized Peripheral Blood Progenitor Cells of Patients Undergoing High-Dose Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Dendritic cells: multi-lineal and multi-functional

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Freezing of dendritic cells, generated from cryopreserved leukaphereses, does not influence their ability to induce antigen-specific immune responses or functionally react to maturation stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Tumor-dendritic cell fusion technology and immunotherapy strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Dendritic cells injected via different routes induce immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Kinetics of TCR use in response to repeated epitope-specific immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

1 reference

7 January 2021

The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Characteristics of antigen-independent and antigen-dependent interaction of dendritic cells with CD4+ T cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Intercellular adhesion molecule-3 is the predominant co-stimulatory ligand for leukocyte function antigen-1 on human blood dendritic cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

A comparison of techniques for introducing macromolecules into living cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

RNA-transfected dendritic cells in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Clinical trial designs for the early clinical development of therapeutic cancer vaccines

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

The optimization of helper T lymphocyte (HTL) function in vaccine development

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0463.2003.11107813.X

7 January 2021

10.1034/J.1600-0463.2003.11107813.X

Identifiers

DOI

1 reference

7 August 2017

1 reference